Long-term clinical outcome after intramuscular transplantation of granulocyte colony stimulating factor-mobilized CD34 positive cells in patients with critical limb ischemia

Atherosclerosis

Volumn 224, Issue 2, 2012, Pages 440-445

  Kinoshita, Makoto ^a,b   Fujita, Yasuyuki ^a   Katayama, Minako ^a   Baba, Rie ^a   Shibakawa, Maki ^a   Yoshikawa, Kimiko ^a   Katakami, Nobuyuki ^a   Furukawa, Yutaka ^b   Tsukie, Tomio ^b   Nagano, Tohru ^b   Kurimoto, Yasuo ^b   Yamasaki, Kazuo ^b   Handa, Nobuhiro ^b   Okada, Yukikatsu ^b   Kuronaka, Kaori ^c   Nagata, Yukiko ^c   Matsubara, Yoshihiro ^c   Fukushima, Masanori ^c   Asahara, Takayuki ^a,d   Kawamoto, Atsuhiko ^a  

^a INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^b KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^c Translational Research Informatics Center   (Japan)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Autologous stem cell transplantation; CD34; Clinical trials

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AMPUTATION; ANKLE BRACHIAL INDEX; ARTICLE; ATHEROSCLEROSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; BUERGER DISEASE; CAUSE OF DEATH; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CRITICAL LIMB ISCHEMIA; DISEASE COURSE; EVENT FREE SURVIVAL; EXERCISE TOLERANCE; FEMALE; GANGRENE; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; LEG ULCER; LEUKAPHERESIS; MALE; OVERALL SURVIVAL; PAIN ASSESSMENT; PATIENT SAFETY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RATING SCALE; RETREATMENT; STEM CELL MOBILIZATION; TREATMENT OUTCOME; ULCER HEALING;

ADULT; AGED; AMPUTATION; ANTIGENS, CD34; BIOLOGICAL MARKERS; CHRONIC DISEASE; CRITICAL ILLNESS; DISEASE-FREE SURVIVAL; ENDOTHELIAL CELLS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INJECTIONS, INTRAMUSCULAR; ISCHEMIA; JAPAN; LIMB SALVAGE; LINEAR MODELS; LOWER EXTREMITY; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; RECOVERY OF FUNCTION; REOPERATION; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; THROMBOANGIITIS OBLITERANS; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866557505     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.07.031     Document Type: Article

References (27)

1. Hirsch A.T., Haskal Z.J., Hertzer N.R., et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American association for vascular surgery/society for vascular surgery, society for cardiovascular angiography and interventions, society for vascular medicine and biology, society of interventional radiology, and the ACC/AHA task force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease) endorsed by the American association of cardiovascular and pulmonary rehabilitation; national heart, lung, and blood institute; society for vascular nursing; transatlantic inter-society consensus; and vascular disease foundation. J Am Coll Cardiol 2006, 47:1239-1312.
2. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007, 45(Suppl. S):S5-67.
3. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
4. Kalka C., Masuda H., Takahashi T., et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A 2000, 97:3422-3427.
5. Kawamoto A., Gwon H.C., Iwaguro H., et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001, 103:634-637.
6. Taguchi A., Soma T., Tanaka H., et al. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest 2004, 114:330-338.
7. Tateishi-Yuyama E., Matsubara H., Murohara T., et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002, 360:427-435.
8. Tateno K., Minamino T., Toko H., et al. Critical roles of muscle-secreted angiogenic factors in therapeutic neovascularization. Circ Res 2006, 98:1194-1202.
9. Onodera R., Teramukai S., Tanaka S., et al. Bone marrow mononuclear cells versus G-CSF-mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled analysis for long-term prognosis. Bone Marrow Transplant 2011, 46:278-284.
10. Kawamoto A., Katayama M., Handa N., et al. Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial. Stem Cells 2009, 27:2857-2864.
11. Burt R.K., Testori A., Oyama Y., et al. Autologous peripheral blood CD133+ cell implantation for limb salvage in patients with critical limb ischemia. Bone Marrow Transplant 2010, 45:111-116.
12. Matoba S., Tatsumi T., Murohara T., et al. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (therapeutic angiogenesis by cell transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J 2008, 156:1010-1018.
13. Moriya J., Minamino T., Tateno K., et al. Long-term outcome of therapeutic neovascularization using peripheral blood mononuclear cells for limb ischemia. Circ Cardiovasc Interv 2009, 2:245-254.
14. Horie T., Onodera R., Akamastu M., et al. Long-term clinical outcomes for patients with lower limb ischemia implanted with G-CSF-mobilized autologous peripheral blood mononuclear cells. Atherosclerosis 2010, 208:461-466.
15. Idei N., Soga J., Hata T., et al. Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and Buerger disease. Circ Cardiovasc Interv 2011, 4:15-25.
16. Miyamoto K., Nishigami K., Nagaya N., et al. Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans. Circulation 2006, 114:2679-2684.
17. Vasa M., Fichtlscherer S., Aicher A., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001, 89:E1-E7.
18. Tepper O.M., Galiano R.D., Capla J.M., et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002, 106:2781-2786.
19. Yamamoto K., Kondo T., Suzuki S., et al. Molecular evaluation of endothelial progenitor cells in patients with ischemic limbs: therapeutic effect by stem cell transplantation. Arterioscler Thromb Vasc Biol 2004, 24:e192-e196.
20. Losordo D.W., Henry T.D., Davidson C., et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res 2011, 109:428-436.
21. Mifune Y., Matsumoto T., Kawamoto A., et al. Local delivery of granulocyte colony stimulating factor-mobilized CD34-positive progenitor cells using bioscaffold for modality of unhealing bone fracture. Stem Cells 2008, 26:1395-1405.
22. Nakamura T., Tsutsumi V., Torimura T., et al. Human peripheral blood CD34-positive cells enhance therapeutic regeneration of chronically injured liver in nude rats. J Cell Physiol 2012, 227:1538-1552.
23. Huang P., Li S., Han M., Xiao Z., Yang R., Han Z.C. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005, 28:2155-2160.
24. Prochazka V., Gumulec J., Jaluvka F., et al. Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer. Cell Transplant 2010, 19:1413-1424.
25. Walter D.H., Krankenberg H., Balzer J.O., et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv 2011, 4:26-37.
26. Benoit E., O'Donnell T.F., Iafrati M.D., et al. The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design. J Transl Med 2011, 9:165.
27. Iafrati M.D., Hallett J.W., Geils G., et al. Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia. J Vasc Surg 2011, 54:1650-1658.